I-MAB (IMAB) Pre-Tax Income : $-204.95 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. I-MAB's pretax income for the six months ended in Dec. 2023 was $-97.04 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-204.95 Mil. I-MAB's pretax margin was -8,672.21%.

During the past 7 years, I-MAB's highest Pretax Margin was 1131.35%. The lowest was -5304.17%. And the median was -2580.38%.

I-MAB Pre-Tax Income Historical Data

The historical data trend for I-MAB's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Pre-Tax Income Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-207.02

73.88

-366.55

-359.54

-205.27

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial								-197.05	-156.36	-209.38	-107.91	-97.04

Competitive Comparison of I-MAB's Pre-Tax Income

For the Biotechnology subindustry, I-MAB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where I-MAB's Pre-Tax Income falls into.

I-MAB Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

I-MAB's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-171.157	+	-41.263	+	-0.101	+	7.248	+	-0.00099999999997635
	=	-205.27

I-MAB's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-77.074	+	-22.871	+	-0.07	+	2.974	+	-0.001000000000019
	=	-97.04

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-204.95 Mil.

I-MAB (NAS:IMAB) Pre-Tax Income Explanation

I-MAB's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-97.042	/	1.119
	=	-8,672.21%

During the past 7 years, I-MAB's highest Pretax Margin was 1131.35%. The lowest was -5304.17%. And the median was -2580.38%.

I-MAB Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of I-MAB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.